Prices on some 350 drugs are headed up, says a new report from Reuters and FiercePharma. And many of those are big names.

“Already, list prices on big-selling products such as AbbVie’s Imbruvica, AstraZeneca’s Tagrisso, Gilead Sciences’ Biktarvy, GSK’s Shingrix and Pfizer’s Ibrance have gone up to start the year, a database from 46brooklyn shows,” FiercePharma reports.

For the FiercePharma story, read:

For the Reuters report, see: